Eric Lefkofsky’s Startup Tempus Uses a Data Driven Approach to Help Physicians Provide Cancer Treatment Plans
Eric Lefkofsky’s latest startup venture Tempus recently made a huge announcement: an additional $70 million in funding to the healthcare tech company. The additional influx of investment capital was part of a third round of funding, called a Series C funding round and it brings the total funding for Tempus to $130 million in investments.
The Series C funding influx brings Tempus to an estimated valuation of $700 million. This is just an estimate but still great news for this company that is by any means a baby startup, founded in 2015.
Eric Lefkofsky chose to co-found a company in the healthcare and medical fields after seeing such massive longterm success in the tech field after he put together some of the pieces of the cancer treatment plan process and realized there were some gaps. He noticed that while there was a huge amount of data being collected on each patient, it was typically housed within physicians notes on individual casess and not accessible in any digitized system that was accessible to all oncologists. Tempus’s main goal is to provide better patient outcomes for loved ones undergoing cancer treatment.
Additionally, he and his team believe greatly in the power of human genome sequencing to map out individual data in relation to their cancer treatments. While the cost of genomic sequencing has dropped significantly and it has proven to provide great amounts of data, it still wasn’t regularly used. These were the two gaps that Tempus wants to fill.
Eric Lefkofsky used the power of what he knows best to found Tempus: Technology. By gathering patient care data and human genome sequencing data, Tempus seeks to build the largest library of clinic data and molecular data that the world has ever seen. This data will then be accessible to doctors everywhere in a simple operating system.
With the influx of funding Tempus has already put its goals into tangible action by working with some of medical research’s biggest names. Among those are the Mayo Clinic and Duke University’s School of Medicine.
With Lefkofsky at the helm and a $700 million valuation, Tempus is on the move to becoming one of biggest startups in the healthcare and technology industries to date.